Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of April 30, 2013:
- Total Issued Shares: 5,421,767,041 Ordinary Shares of 25p each.
- Treasury Shares: 498,431,327 Ordinary Shares.
- Total Voting Rights: 4,923,335,714.
The filing does not explicitly state material changes compared to a prior comparable period, though the specific share counts are provided for shareholder notification calculations.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,923,335,714) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (498,431,327) to calculate the net outstanding share count.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.